Austin, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The SNS Insider report indicates that, “The Anti-Fungal Treatment Market was valued at USD 16 Billion in 2023 and is projected to reach USD 22.19 Billion by 2032, growing at a compound annual growth rate (CAGR) of 3.75% from 2024 to 2032.”
Increase in Chronic Conditions and Antibiotic Resistance Accelerate Demand in the Anti-Fungal Treatment Market
The Anti-Fungal Treatment Market has seen steady growth, driven by an increase in fungal infections linked to chronic conditions such as diabetes, cancer, and HIV/AIDS. In 2023, 1.96 million new cancer cases and 609,820 cancer-related deaths were projected in the U.S., with 39.9 million people globally living with HIV. These conditions weaken the immune system, heightening the risk of fungal diseases, and thus escalating the demand for antifungal treatments. Improved diagnostics and healthcare infrastructure further support early detection and treatment.
The rise in antibiotic resistance is also fueling demand for antifungals, as healthcare systems seek alternative treatments for drug-resistant fungal strains. The growing adoption of advanced antifungal therapies, especially those with fewer side effects, benefits both developed and emerging markets. Retail availability of over-the-counter antifungals and self-medication is broadening market reach. As research into novel therapies and targeted treatments continues, the antifungal market is poised for continued growth in the coming years.
Download PDF Sample of Anti-Fungal Treatment Market @ https://www.snsinsider.com/sample-request/2651
Key Players:
- Abbott - (Abbott Fungistat, Cresemba)
- bioMérieux SA - (VITEK 2, BioFire FilmArray)
- Cardinal Health - (Nystatin, Lamisil)
- F. Hoffmann-La Roche Ltd - (Diflucan, MycoGuard)
- BD - (BD BBL CHROMagar, BD Phoenix System)
- Hologic - (Panther Fusion, Aptima)
- Siemens Medical Solutions - (Atellica Solution, Immulite)
- Quest Diagnostics - (T2Candida Panel, PCR Fungal Tests)
- Koninklijke Philips N.V. - (Philips Luminous, Philips Imaging Solutions)
- Pfizer - (Diflucan, Nizoral)
- Johnson & Johnson - (Lotrimin, Lamisil)
- Bayer AG - (Canesten, Daktarin)
- Novartis AG - (Exelderm, Lotrimin)
- Merck KGaA - (Cancidas, Vormulon)
- Gilead Sciences - (AmBisome, Vistide)
- Cipla - (Fluconazole, Ketoconazole)
- Sanofi S.A. - (Diflucan, Fluconazole)
- GlaxoSmithKline - (Lamprene, Betadine)
- Mylan N.V. - (Fluconazole, Ketoconazole)
- Teva Pharmaceutical Industries - (Fluconazole, Ketoconazole)
- Sun Pharmaceutical Industries - (Terbinafine, Fluconazole)
- Apotex - (Fluconazole, Nystatin)
- Amneal Pharmaceuticals - (Nystatin, Ketoconazole)
- Zydus Cadila - (Miconazole, Fluconazole)
- Aurobindo Pharma - (Clotrimazole, Fluconazole)
- Sandoz (Mycamine, Fungizone)
- GSK (Brexafemme, Tinactin)
Anti-Fungal Treatment Market Report Scope:
| Report Attributes | Details |
| Market Size in 2023 | USD 16 Billion |
| Market Size by 2032 | USD 22.19 Billion |
| CAGR | CAGR of 3.75% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class (Azoles, Polyenes, Allylamines, Echinocandins) • By Infection Type (Superficial Antifungal Infections, Systemic Antifungal Infections) • By Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) • By Dosage Form (Oral Drugs, Ointments, Powders, Others) • By End User (Hospitals & Clinics, Dermatology Clinics, Others) |
| Key Drivers | • Growing Awareness of Fungal Infections Drives Demand for Antifungal Treatments • Rising Use of Immunosuppressive Drugs Expands Demand for Antifungal Treatments |
If You Need Any Customization on Anti-Fungal Treatment Market Report, Inquire Now @ https://www.snsinsider.com/enquiry/2651
Dominance of Superficial Antifungal Infections and Rapid Growth of Systemic Antifungal Infections
The Superficial Antifungal Infections segment led the anti-fungal treatment market in 2023, accounting for approximately 67% of total revenue. This dominance is driven by the high prevalence of common superficial infections like athlete’s foot and ringworm, which are effectively treated with affordable, over-the-counter antifungal medications.
The Systemic Antifungal Infections segment, however, is anticipated to experience the fastest growth, with a projected CAGR of 5.33% from 2024 to 2032. This growth is attributed to an increasing number of immunocompromised individuals, such as those undergoing chemotherapy or organ transplants, requiring more advanced, prescription-based antifungal treatments.
The dominance of Dermatology Clinics and Growth of Hospitals & Clinics
The Dermatology Clinics segment dominated the anti-fungal treatment market in 2023, holding around 50% of the market share. This is due to the widespread treatment of common fungal skin infections, such as athlete's foot and ringworm, in these specialized clinics. The availability of effective, targeted treatments in dermatology clinics has made them the preferred choice for many patients with superficial fungal infections.
The Hospitals & Clinics segment is expected to grow at the fastest rate, with a projected CAGR of 5.15% from 2024 to 2032. This growth is attributed to the rising number of immunocompromised patients and the increasing complexity of systemic fungal infections. Hospitals and clinics provide advanced diagnostic tools and specialized treatments, which are essential for managing severe and invasive fungal infections.
Oral Drugs Lead Anti-Fungal Treatment Market, Ointments Segment Shows Rapid Growth
The Oral Drugs segment captured the largest share of the anti-fungal treatment market, accounting for about 55% of the revenue in 2023. This is due to the convenience and proven effectiveness of oral medications in treating both superficial and systemic fungal infections, making them the preferred choice for patients and healthcare providers.
The Ointments segment is expected to grow at the fastest CAGR of 4.92% from 2024 to 2032, driven by a growing preference for topical treatments. These non-invasive options, which offer ease of application and fewer systemic side effects, are particularly appealing for mild, localized fungal conditions like athlete’s foot and ringworm.
North America Leads Market, Asia Pacific Expected to Grow Fastest
North America held the largest share of the anti-fungal treatment market in 2023, contributing approximately 41% to the overall revenue. This dominance is attributed to the region's well-established healthcare system, widespread awareness of fungal infections, and a strong presence of key pharmaceutical companies. Furthermore, North America's extensive range of available antifungal treatments and significant investments in research and development solidify its leading position in the market.
In contrast, the Asia Pacific region is projected to grow at the fastest CAGR of 6.02% from 2024 to 2032. The region’s rapid growth is driven by improved healthcare access, increasing awareness of fungal infections, and a higher prevalence of diabetes, which makes populations more vulnerable to fungal diseases. Moreover, expanding middle-class populations and better healthcare systems in emerging markets like India and China are boosting the demand for antifungal treatments.
Buy Full Research Report on Anti-Fungal Treatment Market 2024-2032 @ https://www.snsinsider.com/checkout/2651
Key Developments in the Anti-Fungal Treatment Market
- In 2023, Sandoz acquired global rights to Mycamine (micafungin sodium) from Astellas, enhancing its hospital and anti-infectives portfolio while supporting the fight against antimicrobial resistance (AMR).
- On March 30, 2023, GSK and SCYNEXIS entered into an exclusive agreement to commercialize Brexafemme (ibrexafungerp), a novel antifungal treatment for vulvovaginal candidiasis and recurrent infections.
Table of Contents – Major Key Points
1. Introduction
- Market Definition
- Scope (Inclusion and Exclusions)
- Research Assumptions
2. Executive Summary
- Market Overview
- Regional Synopsis
- Competitive Summary
3. Research Methodology
- Top-Down Approach
- Bottom-up Approach
- Data Validation
- Primary Interviews
4. Market Dynamics Impact Analysis
- Market Driving Factors Analysis
- PESTLE Analysis
- Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
- Incidence and Prevalence (2023)
- Prescription Trends, (2023), by Region
- Drug Volume: Production and usage volumes of pharmaceuticals.
- Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
- List of Major Companies, By Region
- Market Share Analysis, By Region
- Product Benchmarking
- Strategic Initiatives
- Technological Advancements
- Market Positioning and Branding
7. Anti-Fungal Treatment Market Segmentation, by Infection Type
8. Anti-Fungal Treatment Market Segmentation, By Therapeutic Indications
9. Anti-Fungal Treatment Market Segmentation, By Drug Class
10. Anti-Fungal Treatment Market Segmentation, By End User
11. Anti-Fungal Treatment Market Segmentation, By Dosage Form
12. Regional Analysis
13. Company Profiles
14. Use Cases and Best Practices
15. Conclusion
Speak with Our Expert Analyst Today to Gain Deeper Insights @ https://www.snsinsider.com/request-analyst/2651
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
